Literature DB >> 3291979

Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up.

F R Appelbaum1, L D Fisher, E D Thomas.   

Abstract

We previously published the results of a prospective comparison of continued chemotherapy or marrow transplantation for adults with acute nonlymphocytic leukemia (ANL) who had achieved a first remission. This report updates that study now that greater than 5 years have passed since the last patient was entered. Among 86 patients eligible for comparison, 43 had no donors and were treated with continued chemotherapy, 43 had donors, but 10 declined transplantation and 33 were transplanted. Five-year disease-free survivals are 21% for the chemotherapy group, 48% for the transplant group, and 10% for the group with matched siblings who declined transplantation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291979

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia.

Authors:  R Willemze; W E Fibbe; J C Kluin-Nelemans; J H Falkenburg; D J Richel; W G Peters; G J den Ottolander; A Brand; F E Zwaan
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

Review 2.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

Review 3.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

Review 4.  Bone marrow transplantation.

Authors:  R L Soutar; D J King
Journal:  BMJ       Date:  1995-01-07

5.  Survival-weighted health profile for long-term survivors of acute myelogenous leukemia.

Authors:  Chiun Hsu; Jung-Der Wang; Jing-Shiang Hwang; Hwei-Fang Tien; Shueh-Mei Chang; Ann-Lii Cheng; Yao-Chang Chen; Jih-Luh Tang
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

6.  Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe₃O₄ combined with cyclosporin A in murine models.

Authors:  Jian Cheng; Ying Zhou; Baoan Chen; Jun Wang; Guohua Xia; Nan Jin; Jiahua Ding; Chong Gao; Gouming Chen; Yushan Miao; Weilan Li; Ziling Liu; Xuemei Wang
Journal:  Int J Nanomedicine       Date:  2011-10-03

7.  A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.

Authors:  D J Gottlieb; M K Brenner; H E Heslop; A C Bianchi; C Bello-Fernandez; A B Mehta; A C Newland; A R Galazka; E M Scott; A V Hoffbrand
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

8.  High-dose therapy: the Third UCH Meeting.

Authors:  R Chopra
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

9.  Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.

Authors:  Y Belkacémi; F Pène; E Touboul; B Rio; V Leblond; N C Gorin; A Laugier; C Gemici; M Housset; M Ozsahin
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.